Genelux Corp. (GNLX)
NASDAQ:GNLX
GNLX Stock Chart & Stats
$2.57
-$0.06(-2.24%)
At close: 4:00 PM EST
$2.57
-$0.06(-2.24%)
Day’s Range― - ―
52-Week Range$1.99 - $8.54
Previous CloseN/A
Volume23.79K
Average Volume (3M)156.94K
Market Cap
$115.15M
Enterprise Value$93.03M
Total Cash (Recent Filing)$14.60M
Total Debt (Recent Filing)$1.69M
Price to Earnings (P/E)―
Beta0.82
Next Earnings
May 13, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding44,805,813
10 Day Avg. Volume178,540
30 Day Avg. Volume156,945
Financial Highlights & Ratios
PEG Ratio0.53
Price to Book (P/B)14.04
Price to Sales (P/S)20261.21
P/FCF Ratio-6.15
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue11.63K
Enterprise Value/Gross Profit-328.72
Enterprise Value/Ebitda-2.85
Forecast
1Y Price Target
$21.00Price Target Upside717.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.82
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financing And Market InterestRecent equity financing and available cash provide runway to reach key clinical milestones while renewed investor and regulatory interest in oncolytic viruses may increase market visibility.
Mechanism Of ActionOlvi-Vec combines direct tumor lysis, tumor-specific immune activation, and resensitization to platinum chemotherapy through STAT1 upregulation, offering a clear scientific rationale for combination approaches in hard-to-treat tumors.
Registrational Trial ProgressPhase 3 registrational study in platinum-resistant ovarian cancer continues enrolling with an independent data monitoring committee recommending continuation, supporting a credible path toward a pivotal readout.
Bears Say
Dose Optimization UncertaintyAdditional dose-finding is required because variable responses across small early cohorts leave uncertainty about the optimal dose for broader development plans.
Limited Follow-upShort follow-up in reported cohorts creates uncertainty about the durability of responses and the longer-term safety profile.
Small Sample SizesEarly lung studies rely on very small patient cohorts, which limits statistical confidence and raises the risk that initial efficacy signals will not hold in larger trials.
Genelux Corp. News
GNLX FAQ
What was Genelux Corp.’s price range in the past 12 months?
Genelux Corp. lowest stock price was $1.99 and its highest was $8.54 in the past 12 months.
What is Genelux Corp.’s market cap?
Genelux Corp.’s market cap is $115.15M.
When is Genelux Corp.’s upcoming earnings report date?
Genelux Corp.’s upcoming earnings report date is May 13, 2026 which is in 36 days.
How were Genelux Corp.’s earnings last quarter?
Genelux Corp. released its earnings results on Mar 19, 2026. The company reported -$0.24 earnings per share for the quarter, missing the consensus estimate of -$0.218 by -$0.022.
Is Genelux Corp. overvalued?
According to Wall Street analysts Genelux Corp.’s price is currently Undervalued.
Does Genelux Corp. pay dividends?
Genelux Corp. does not currently pay dividends.
What is Genelux Corp.’s EPS estimate?
Genelux Corp.’s EPS estimate is -0.2.
How many shares outstanding does Genelux Corp. have?
Genelux Corp. has 44,805,813 shares outstanding.
What happened to Genelux Corp.’s price movement after its last earnings report?
Genelux Corp. reported an EPS of -$0.24 in its last earnings report, missing expectations of -$0.218. Following the earnings report the stock price went down -5.512%.
Which hedge fund is a major shareholder of Genelux Corp.?
Currently, no hedge funds are holding shares in GNLX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Genelux Corp. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.00 (717.12% Upside)
$21.00 (717.12% Upside)
Hedge Fund Trend
Decreased
By 631.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $14.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
136.72%
12-Months-Change
Fundamentals
Return on Equity
-98.72%
Trailing 12-Months
Asset Growth
-28.62%
Trailing 12-Months
Company Description
Genelux Corp.
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
GNLX Stock 12 Month Forecast
Average Price Target
$21.00
▲(717.12% Upside)
Technical Analysis
Coherus Biosciences
―
Fate Therapeutics
―
Tonix Pharma
―
Corbus Pharmaceuticals
―
Forte Biosciences
―
Ownership Overview
3.70% Insiders
3.85% Mutual Funds
9.45% Other Institutional Investors
79.37% Public Companies and
Individual Investors